Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma

M. Colleoni, G. Liessi, G. Mastrapasqua, P. Nelli, G. Vicario, G. Sgarbossa, F. Pancheri, P. Manente

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Unresectable hepatocellular carcinoma is related to a poor prognosis. Encouraging response rates and survival have been reported with intra-arterial (i.a.) chemotherapy and chemo-embolisation, but limited data are available on the association of the two treatment modalities. We therefore started a new programme combining i.a. chemotherapy with chemo-embolisation. The treatment regimen consisted of L-leucovorin (100 mg/m 2 i.v.), 5-fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemo-embolisation with mitoxantrone (10 mg/m 2) plus ethiodized oil followed immediately. The same treatment plus gelatin sponge was given after 28 days. 26 patients entered the study and were evaluable for response and side-effects. Main patient characteristics were: males 21, females 5: median age 68 years (range 42-76 years); stage TNM II-III 17, IVA 9; Child's A 12, Child's B 14; elevated baseline α-fetoprotein 17; cirrhosis 25. 14 patients had a partial response (54%; 95% confidence interval 33-73%), 3 had stabilisation and 9 had progressive disease. Median survival was 11 months (range 2-20+). 16 patients had grade I-II pain and 15 grade I-II fever. Our results indicate that the regimen is safe, well tolerated and capable of inducing objective remissions in a high percentage of patients with hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)56-60
Number of pages5
JournalEuropean Journal of Cancer
Volume33
Issue number1
DOIs
Publication statusPublished - Jan 1997

Fingerprint

Hepatocellular Carcinoma
Drug Therapy
Fetal Proteins
Ethiodized Oil
Mitoxantrone
compound A 12
Leucovorin
Carboplatin
Porifera
Gelatin
Fluorouracil
Fibrosis
Fever
Therapeutics
Survival Rate
Confidence Intervals
Pain
Survival

Keywords

  • chemo-embolisation
  • hepatocellular
  • intra-arterial chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. / Colleoni, M.; Liessi, G.; Mastrapasqua, G.; Nelli, P.; Vicario, G.; Sgarbossa, G.; Pancheri, F.; Manente, P.

In: European Journal of Cancer, Vol. 33, No. 1, 01.1997, p. 56-60.

Research output: Contribution to journalArticle

Colleoni, M, Liessi, G, Mastrapasqua, G, Nelli, P, Vicario, G, Sgarbossa, G, Pancheri, F & Manente, P 1997, 'Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma', European Journal of Cancer, vol. 33, no. 1, pp. 56-60. https://doi.org/10.1016/S0959-8049(96)00307-3
Colleoni, M. ; Liessi, G. ; Mastrapasqua, G. ; Nelli, P. ; Vicario, G. ; Sgarbossa, G. ; Pancheri, F. ; Manente, P. / Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. In: European Journal of Cancer. 1997 ; Vol. 33, No. 1. pp. 56-60.
@article{f5712e4ccd474fb6a4c32121d9ebab6e,
title = "Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma",
abstract = "Unresectable hepatocellular carcinoma is related to a poor prognosis. Encouraging response rates and survival have been reported with intra-arterial (i.a.) chemotherapy and chemo-embolisation, but limited data are available on the association of the two treatment modalities. We therefore started a new programme combining i.a. chemotherapy with chemo-embolisation. The treatment regimen consisted of L-leucovorin (100 mg/m 2 i.v.), 5-fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemo-embolisation with mitoxantrone (10 mg/m 2) plus ethiodized oil followed immediately. The same treatment plus gelatin sponge was given after 28 days. 26 patients entered the study and were evaluable for response and side-effects. Main patient characteristics were: males 21, females 5: median age 68 years (range 42-76 years); stage TNM II-III 17, IVA 9; Child's A 12, Child's B 14; elevated baseline α-fetoprotein 17; cirrhosis 25. 14 patients had a partial response (54{\%}; 95{\%} confidence interval 33-73{\%}), 3 had stabilisation and 9 had progressive disease. Median survival was 11 months (range 2-20+). 16 patients had grade I-II pain and 15 grade I-II fever. Our results indicate that the regimen is safe, well tolerated and capable of inducing objective remissions in a high percentage of patients with hepatocellular carcinoma.",
keywords = "chemo-embolisation, hepatocellular, intra-arterial chemotherapy",
author = "M. Colleoni and G. Liessi and G. Mastrapasqua and P. Nelli and G. Vicario and G. Sgarbossa and F. Pancheri and P. Manente",
year = "1997",
month = "1",
doi = "10.1016/S0959-8049(96)00307-3",
language = "English",
volume = "33",
pages = "56--60",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma

AU - Colleoni, M.

AU - Liessi, G.

AU - Mastrapasqua, G.

AU - Nelli, P.

AU - Vicario, G.

AU - Sgarbossa, G.

AU - Pancheri, F.

AU - Manente, P.

PY - 1997/1

Y1 - 1997/1

N2 - Unresectable hepatocellular carcinoma is related to a poor prognosis. Encouraging response rates and survival have been reported with intra-arterial (i.a.) chemotherapy and chemo-embolisation, but limited data are available on the association of the two treatment modalities. We therefore started a new programme combining i.a. chemotherapy with chemo-embolisation. The treatment regimen consisted of L-leucovorin (100 mg/m 2 i.v.), 5-fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemo-embolisation with mitoxantrone (10 mg/m 2) plus ethiodized oil followed immediately. The same treatment plus gelatin sponge was given after 28 days. 26 patients entered the study and were evaluable for response and side-effects. Main patient characteristics were: males 21, females 5: median age 68 years (range 42-76 years); stage TNM II-III 17, IVA 9; Child's A 12, Child's B 14; elevated baseline α-fetoprotein 17; cirrhosis 25. 14 patients had a partial response (54%; 95% confidence interval 33-73%), 3 had stabilisation and 9 had progressive disease. Median survival was 11 months (range 2-20+). 16 patients had grade I-II pain and 15 grade I-II fever. Our results indicate that the regimen is safe, well tolerated and capable of inducing objective remissions in a high percentage of patients with hepatocellular carcinoma.

AB - Unresectable hepatocellular carcinoma is related to a poor prognosis. Encouraging response rates and survival have been reported with intra-arterial (i.a.) chemotherapy and chemo-embolisation, but limited data are available on the association of the two treatment modalities. We therefore started a new programme combining i.a. chemotherapy with chemo-embolisation. The treatment regimen consisted of L-leucovorin (100 mg/m 2 i.v.), 5-fluorouracil (800 mg/m 2 i.a.), and carboplatin (250 mg/m 2 i.a.). Chemo-embolisation with mitoxantrone (10 mg/m 2) plus ethiodized oil followed immediately. The same treatment plus gelatin sponge was given after 28 days. 26 patients entered the study and were evaluable for response and side-effects. Main patient characteristics were: males 21, females 5: median age 68 years (range 42-76 years); stage TNM II-III 17, IVA 9; Child's A 12, Child's B 14; elevated baseline α-fetoprotein 17; cirrhosis 25. 14 patients had a partial response (54%; 95% confidence interval 33-73%), 3 had stabilisation and 9 had progressive disease. Median survival was 11 months (range 2-20+). 16 patients had grade I-II pain and 15 grade I-II fever. Our results indicate that the regimen is safe, well tolerated and capable of inducing objective remissions in a high percentage of patients with hepatocellular carcinoma.

KW - chemo-embolisation

KW - hepatocellular

KW - intra-arterial chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0031038489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031038489&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(96)00307-3

DO - 10.1016/S0959-8049(96)00307-3

M3 - Article

C2 - 9071900

AN - SCOPUS:0031038489

VL - 33

SP - 56

EP - 60

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -